Lai Wai Kwan, Haydon Geoff, Mutimer David, Murphy Nick
Liver Laboratories, University of Birmingham, Birmingham, UK.
Intensive Care Med. 2005 Nov;31(11):1544-9. doi: 10.1007/s00134-005-2786-y. Epub 2005 Sep 10.
To investigate the effect of the molecular adsorbent recirculating system (MARS) on physiological variables in patients with acute liver failure.
A prospective, observational study of MARS in addition to standard medical therapy in the management of patients presenting with acute liver failure.
A regional liver transplant centre.
Ten consecutive patients admitted with acute liver failure with a grade III or IV hepatic encephalopathy.
MARS therapy for 8 h on 2 consecutive days. Standard monitoring included the use of a pulmonary artery catheter and an intracranial pressure monitor.
During the first MARS treatment there was a significant increase in systemic vascular resistance index (SVRI) from 1114+/-196 to 1432+/-245 dyne s(-1) cm(-5) m(-2) with a reduction in cardiac index from 5.5+/-0.6 to 4.2+/-0.4 l min(-1) m(-2). The changes were maintained between the start of the first and second sessions but not to the end of second. Significant clearance of urea and creatinine was observed. Intracranial pressure did not change during the treatments. Overall mortality was 70%.
MARS therapy was well tolerated, with significant increases in vascular tone during the first session. This increase was not sustained over the duration of the study with a return to baseline values by the end of the second session. Based on our experience we cannot recommend the routine use of MARS therapy in acute liver failure outside of a clinical trial.
探讨分子吸附再循环系统(MARS)对急性肝衰竭患者生理变量的影响。
一项前瞻性观察性研究,在急性肝衰竭患者的管理中,除标准药物治疗外加用MARS。
一个地区性肝移植中心。
连续10例因急性肝衰竭伴III级或IV级肝性脑病入院的患者。
连续2天进行8小时的MARS治疗。标准监测包括使用肺动脉导管和颅内压监测仪。
在首次MARS治疗期间,全身血管阻力指数(SVRI)从1114±196显著增加至1432±245达因·秒(-1)·厘米(-5)·米(-2),心脏指数从5.5±0.6降至4.2±0.4升·分钟(-1)·米(-2)。这些变化在第一次和第二次治疗开始之间维持,但到第二次治疗结束时未维持。观察到尿素和肌酐有显著清除。治疗期间颅内压未改变。总体死亡率为70%。
MARS治疗耐受性良好,在第一次治疗期间血管张力显著增加。在研究期间这种增加未持续,到第二次治疗结束时恢复到基线值。根据我们的经验,我们不建议在临床试验之外的急性肝衰竭中常规使用MARS治疗。